Pfizer Unit Gets 'Put Up' Order In Osteoarthritis IP Fight
A London judge ruled Monday that if a Pfizer subsidiary wants to bring an infringement counterclaim against Teva and Regeneron in their challenge to three osteoarthritis treatment patents, it must do...To view the full article, register now.
Already a subscriber? Click here to view full article